Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
Tailored therapy
Eradication
Disease Progression
Alkylating agents
Gene expression
Epigénétiques
Biologics
Immune cells
Colorectal cancer
Gènes
RISK
Stricture
Helicobacter pylori
Screening
Vedolizumab
PCR
Over 80s
COLON-CANCER
Consensus
Cost effectiveness
Colon cancer
Small molecules
Colorectal cancer Colibactin and lipids
Crohn's disease
Anti-TNF
Microbiota
Effectiveness
Survival
Anti-TNF agents
Colon
Fecal microbiota
Inclusion
MALT
MORTALITY
Ustekinumab
Therapeutics
DNA METHYLATION
Bacteria
Neoadjuvant chemotherapy
Drug
Intestinal crypts
Colectomy
Bactéries
Disability
MARKER
Safety
Dysbiose
Thérapie ciblée
Inhibitor
Methylation
Upper gastrointestinal tract
Cell adhesion
Résistance
HIV
Heart disease risk factors
IL12
Surgery
Dysbiosis
Resistance
Inflammatory Bowel Diseases
Inflammatory bowel diseases
Clinical trial
CARCINOGENESIS
Patients experience
Contraindication
Parvimonas micra
Biomarker
Tuberculosis
Ulcerative colitis
Clinical guidelines
T1118 translocation
Crohn’s disease
Eligibility
Rituximab plus chlorambucil
MICROBIOTA
Gene methylation
Inflammatory bowel disease
Monitoring
Endoscopic treatment
Colonic epithelial primary cells
Immunosuppressant
Disease progression
DNA methylation
Acceptability
Venous thromboembolism
Patient-reported outcome
Maintenance therapy
Original Article Clinical
18 FDG-PET/CT
Epigenetics
Méthylation
Microbiote
Cancer
Genes
Kidney diseases
Primary sclerosing cholangitis
Rituximab
IL23
IBD
Algorithm
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|